{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:37:21Z","timestamp":1791841041485,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ijid.2019.01.029","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T02:36:48Z","timestamp":1548556608000},"page":"S80-S86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"S","title":["Dengue vaccine development: Global and Indian scenarios"],"prefix":"10.1016","volume":"84","author":[{"given":"Sathyamangalam","family":"Swaminathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2019.01.029_bib0005","series-title":"Access to Vaccines index","year":"2017"},{"key":"10.1016\/j.ijid.2019.01.029_bib0010","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cmi.2018.01.018","article-title":"Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America","volume":"24","author":"Arredondo-Garcia","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2019.01.029_bib0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2019.01.029_bib0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent DNA vaccine administered with a cationic lipid-based adjuvant in a phase I clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijid.2019.01.029_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ijid.2019.01.029_bib0030","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.17-0627","article-title":"Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico","volume":"98","author":"Diaz","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijid.2019.01.029_bib0035","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2019.01.029_bib0040","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.vaccine.2018.03.055","article-title":"Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine","volume":"36","author":"Gromowski","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2019.01.029_bib0045","first-page":"373","article-title":"Dengue in India","volume":"136","author":"Gupta","year":"2012","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijid.2019.01.029_bib0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: hypotheses to understand CYD-TDV-induced protection","volume":"14","author":"Guy","year":"2016","journal-title":"Nature Rev Microbiol"},{"key":"10.1016\/j.ijid.2019.01.029_bib0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4269\/ajtmh.1990.42.179","article-title":"Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study","volume":"42","author":"Guzman","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijid.2019.01.029_bib0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1590\/S1020-49892002000400003","article-title":"Enhanced severity of secondary dengue 2 infections: death rates in 1981 and 1997 Cuban outbreaks","volume":"11","author":"Guzman","year":"2002","journal-title":"Pan Am J Pub Health"},{"key":"10.1016\/j.ijid.2019.01.029_bib0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijid.2019.01.029_bib0070","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1016\/j.vaccine.2017.09.089","article-title":"Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age","volume":"35","author":"Halstead","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2019.01.029_bib0075","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live attenuated, tetravalent dengue vaccine (CYD-TDV) in na\u00efve and dengue-exposed individuals","volume":"125","author":"Henein","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2019.01.029_bib0080","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Trans Med"},{"key":"10.1016\/j.ijid.2019.01.029_bib0085","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.virol.2015.03.025","article-title":"Shake, rattle, and roll: impact of the dynamics of flavivirus particles on their interactions with the host","volume":"479-480","author":"Kuhn","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.ijid.2019.01.029_bib0090","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1016\/j.vaccine.2015.09.101","article-title":"Preclinical and clinical development of a dengue recombinant subunit vaccine","volume":"33","author":"Manoff","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2019.01.029_bib0095","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","article-title":"Immune response to dengue virus and prospects for a vaccine","volume":"29","author":"Murphy","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ijid.2019.01.029_bib0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","article-title":"A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone","volume":"15","author":"Osorio","year":"2016","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.ijid.2019.01.029_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006191","article-title":"A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice","volume":"12","author":"Ramasamy","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2019.01.029_bib0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.1812055115","article-title":"Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies","volume":"116","author":"Raut","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijid.2019.01.029_bib0115","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijid.2019.01.029_bib0120","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.4269\/ajtmh.14-0002","article-title":"Economic and disease burden of dengue illness in India","volume":"91","author":"Shepard","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijid.2019.01.029_bib0125","series-title":"Technology development board enters into an agreement with M\/s Panacea Biotec Pvt Ltd, New Delhi, to complete the late stage development of first Indian dengue vaccine","author":"TDB-Panacea Agreement","year":"2017"},{"key":"10.1016\/j.ijid.2019.01.029_bib0130","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1128\/JVI.00216-15","article-title":"Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute lethal small intestinal pathology without a high level of viremia in mice","volume":"89","author":"Watanabe","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2019.01.029_bib0135","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine: What makes this vaccine different from the Sanofi-Pasteur CYD\u2122 vaccine","volume":"15","author":"Whitehead","year":"2016","journal-title":"Exp Rev Vac"},{"key":"10.1016\/j.ijid.2019.01.029_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005584","article-title":"In a randomized trial, the live attenuated tetravalent vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination","volume":"11","author":"Whitehead","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2019.01.029_bib0145","series-title":"Revision to the background paper from 17th March 2016 prepared by the SAGE working group on dengue vaccines & the WHO secretariat","author":"WHO","year":"2018"},{"key":"10.1016\/j.ijid.2019.01.029_bib0150","series-title":"Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected tropical diseases","author":"WHO","year":"2013"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219300402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219300402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T06:33:48Z","timestamp":1565332428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971219300402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":30,"alternative-id":["S1201971219300402"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2019.01.029","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dengue vaccine development: Global and Indian scenarios","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2019.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}